Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02

Seth A. Rosenthal, Kyoungwha Bae, Kenneth J. Pienta, Mark L. Sobczak, Sucha O. Asbell, Raghu Rajan, Kevin J. Kerlin, Jeff M. Michalski, Howard M. Sandler

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Fingerprint

Dive into the research topics of 'Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02'. Together they form a unique fingerprint.

Medicine & Life Sciences

Physics & Astronomy